Numab Therapeutics AG: Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
NM26-2198 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets for the treatment of moderate to severe atopic dermatitis (AD) Combined single ascending dose
Source: finanznachrichten.de